Inspire Pharmaceuticals, Inc.
4222 Emperor Boulevard
Suite 200
Durham
North Carolina
27703
United States
Tel: 919-941-9777
Fax: 919-941-9797
Website: http://www.inspirepharm.com/
Email: info@inspirepharm.com
About Inspire Pharmaceuticals, Inc.
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire’s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspire’s clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE® (azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye.For more information, visit www.inspirepharm.com.
201 articles about Inspire Pharmaceuticals, Inc.
-
Merck & Co., Inc. to Close Inspire Pharmaceuticals, Inc. Facility, 51 Jobs Axed
7/1/2011
-
Merck & Co., Inc. Completes Acquisition of Inspire Pharmaceuticals, Inc.
5/16/2011
-
Merck & Co., Inc. Announces Successful Completion of Tender Offer for Shares of Inspire Pharmaceuticals, Inc. With Over 75 Percent of Shares Tendered
5/13/2011
-
Inspire Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
5/10/2011
-
Inspire Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
5/10/2011
-
Merck & Co., Inc. and Inspire Pharmaceuticals, Inc. Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire
4/28/2011
-
Inspire Pharmaceuticals, Inc. Postpones Annual Meeting of Stockholders Due to Recently Announced Tender Offer
4/22/2011
-
Inspire Pharmaceuticals, Inc. Announces Webcast of Presentation at Cowen and Company Health Care Conference
3/3/2011
-
Inspire Pharmaceuticals, Inc. Announces Webcast of Presentation at Citi Global Healthcare Conference
2/24/2011
-
Inspire Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2010 Financial Results
2/17/2011
-
Inspire Pharmaceuticals, Inc. Announces Corporate Restructuring; Cuts 27 Pct of Jobs and Drops Lung Drug
2/17/2011
-
Inspire Pharmaceuticals, Inc. Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results and Provide Corporate Update
2/14/2011
-
Inspire Pharmaceuticals, Inc. Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results and Provide Corporate Update
2/14/2011
-
Inspire Pharmaceuticals, Inc. Cystic Fibrosis Drug, Denufosol Tetrasodium Fails Phase 3 Study; Stock Down at Market Close
1/4/2011
-
Inspire Pharmaceuticals, Inc. Release: TIGER-1 Denufosol Phase 3 Trial for Cystic Fibrosis Published in the American Journal of Respiratory and Critical Care Medicine
12/20/2010
-
Inspire Pharmaceuticals, Inc. Announces Launch of DIQUASTM by Santen Pharmaceutical in Japan
12/13/2010
-
Inspire Pharmaceuticals, Inc. Reports Third Quarter 2010 Financial Results
11/4/2010
-
Inspire Pharmaceuticals, Inc. Release: Data Presentations at North American Cystic Fibrosis Conference Highlight Denufosol's Novel Mechanism of Action
10/21/2010
-
Inspire Pharmaceuticals, Inc. Announces Date for Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results
10/21/2010
-
Inspire Pharmaceuticals, Inc. Release: Data to Be Presented at ERS Conference Highlights Potential for Denufosol to Benefit Cystic Fibrosis Patients on Minimal Pharmacotherapy
9/17/2010